الفهرس 
Assessment of statin-induced myopathy in experimental animals: role of coenzyme Q 10
TABLE OF CONTENTSOnly 14 pages are availabe for public view
 |  | from | 151 |  |  |
| | | from | 151 | | |
Abstract
Statins represent the first line treatment of atherosclerotic disorders. Despite their good safety profile, statins can be associated with muscle-related symptoms and elevation of liver transaminases. Myopathy is a well-documented side effect of statins ranging from simple myalgia to myositis with or without CK elevation. Some patients may develop a more severe form of myopathy; rhabdomyolysis accompanied by muscle destruction and myoglobin release. The exact mechanism of statin-induced myopathy has not been yet elucidated. Mitochondrial dysfunction is among the most compelling theories elucidating statin myotoxicity. Depletion of coenzyme Q10 was postulated as a causal factor in statin-induced mitochondrial dysfunction. However, contradictive data are reported concerning the benefits of CoQ10 supplementation in the management of statin-related muscle symptoms.The aim of the present study was the investigation of atorvastatin-induced myopathy in rats with the possible underlining mechanism with respect to mitochondrial dysfunction. The potential protective effect of CoQ10 co-treatment on myopathy was evaluated. In addition, the myotoxic effect of the lipophilic atorvastatin was compared to that of the hydrophilic rosuvastatin. Finally, the effect of combining atorvastatin with gemfibrozil was examined on myopathy indices & mitochondrial dysfunction parameters